Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Next Quarterly Report.
View:
Post by Infinity on Jan 10, 2022 5:41am

Next Quarterly Report.

We did have a Quarterly report on 1st Feb, 2021 for the previous quarter.  Does anyone know if the company plans to follow the date sequence.  Hopefully,  we will another quarterly very soon.
The next report could very well be a Game Changer!!.   It is time to turn on the Turbo for the TLT stock prices!!
Comment by Oilminerdeluxe on Jan 10, 2022 5:45am
I think, others might know better, that the newsletter will come with the Q reports from now on, But if that is every quarter or if exceptions will be made, I do not know
Comment by fredgoodwinson on Jan 10, 2022 8:25am
Any announcement date that keeps the MMs guessing will be well timed.   ‘The data accrued to date for the TLD 1433-2 open label study for the treatment of NMIBC, seems very encouraging, and Theralase may as well be heading towards fulfilling the necessary outcome requirements to apply for a “BTD from the FDA very soon.’   This one sentence of Vera`s represented pretty much the ...more  
Comment by Infinity on Jan 10, 2022 10:06am
I like the way you presented the statement from Vera.  Again after a long time the CEO is finally talking about SHARE HOLDER VALUES!!  Quote from 15th Nov, 2021 News letter.   Dr. Mandel, CSO and Interim CEO of Theralase® stated, “I am honored to return as the Interim CEO for the Company, as the Company realigns its executive management team to focus on the Company’s ...more  
Comment by Infinity on Jan 10, 2022 10:08am
I like the way you presented the statement from Vera.@ Again after a long time the CEO is finally talking about SHARE HOLDER VALUES!! Quote from 15th Nov, 2021 News letter. Dr. Mandel, CSO and Interim CEO of Theralase@ stated, @I am honored to return as the Interim CEO for the Company, as the Company realigns its executive management team to focus on the Company@s primary objective of ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250